Piper Jaffray analyst Tyler Van Buren kept his Neutral rating and $75 price target on Ionis Pharmaceuticals after its Q1 results with Spinraza royalties and Tegsedi sales seen “in line with expectations”. The analyst believes that the company’s pipeline is maturing as it gets ready to launch Waylivra in Europe next quarter and also sees its Huntington’s OLE continuing to progress. Van Buren contends that Ionis Pharmaceuticals stock is “becoming more interesting” from a long term investment perspective given the recent pullback in price.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.